種瀬 啓士

Medicine & Life Sciences

1. Melanoma 100%
2. Extramammary Paget's Disease 75%
3. Skin 49%
4. Neoplasms 45%
5. Basal Cell Carcinoma 44%
6. Hedgehogs 33%
7. Survival 32%
8. Annular Erythema 32%
9. ixekizumab 31%
10. Primary Hypertrophic Osteoarthropathy 31%
11. Therapeutics 29%
12. Nivolumab 22%
13. Safety 19%
14. Atopic Dermatitis 19%
15. ASP2151 19%
16. G-Protein-Coupled Receptors 18%
17. Neoplasm Metastasis 18%
18. Psoriasis 18%
19. Macrophage Migration-Inhibitory Factors 18%
20. Tumor Biomarkers 18%
21. Apoptosis 17%
22. Skin Neoplasms 17%
23. benralizumab 16%
24. Ligands 16%
25. Staining and Labeling 16%
26. Device Approval 16%
27. dupilumab 15%
28. Bowen's Disease 15%
29. Tubular Sweat Gland Adenomas 15%
30. Nitric Oxide Synthase Type II 15%
31. Poroma 15%
32. Endothelin-2 15%
33. Imiquimod 15%
34. Lymph Nodes 15%
35. Actinic Keratosis 14%
36. Acrospiroma 14%
37. Squamous Cell Carcinoma 14%
38. Monoacylglycerol Lipases 14%
39. Epirubicin 14%
40. Antibodies 14%
41. Phase II Clinical Trials 13%
42. TP protocol 13%
43. pembrolizumab 13%
44. Keratin-19 12%
45. Encephalocele 12%
46. Combined Vaccines 12%
47. Carboplatin 12%
48. Recurrence 12%
49. Hydroxychloroquine 12%
50. Wilms' Tumor Genes 12%